Overweight , ObesityNCT07395466
Improving Weight Loss in Healthy Adults With Overweight and Obesity: An Artificial Intelligence-assisted Dietary Prediction and Prevention System With Continuous Glucose Monitoring
A study testing eTRIP and FatSecret in people with Overweight , Obesity and Overweight or Obese Adults, run by National University Health System, Singapore at 1 site in Singapore.
Trial summary
This study aims to examine the effectiveness of a novel dietary lapse prediction and prevention self-regulation app called the eating behaviour trigger-response inhibition program (eTRIP), and the addition of continuous glucose monitoring (CGM), on healthy eating and weight loss in people with overweight and obesity. Read more about this study
- Who is it for?
- Ages 21 to 65 years
- Conditions the study is for
- Overweight , Obesity, Overweight or Obese Adults, Obesity
- What is being tested?
- eTRIP and FatSecret
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 300 participants
- Where
- 1 siteSingapore
- Study dates
- 22 Jan 2025to Jul 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 21 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- are 21-65 years old
- have BMI ≥23 kg/m2
- can comprehend the English language
- uses a smartphone that can download apps
- are willing to perform continuous glucose monitoring (CGM) using the Dexcom continuous glucose monitoring system
- willing to travel to the National University of Singapore (NUS)
- able to provide informed consent
Who cannot join
- are using/intend to use other apps for weight loss;
- are pregnant or lactating (as it would affect weight change and caloric needs)
- are diagnosed severe mental disorders (e.g. major depressive disorder and schizophrenia)
- are on prescribed meal replacements or pharmacotherapy
- have serious medical conditions
- are scheduled for any kind of surgery within the next 6 months
Trial locations and contacts
1 site in 1 country.
About this study
This study aims to examine the effectiveness of a novel dietary lapse prediction and prevention self-regulation app called the eating behaviour trigger-response inhibition program (eTRIP), and the addition of continuous glucose monitoring (CGM), on healthy eating and weight loss in people with overweight and obesity.
- Being tested
- eTRIP, FatSecret
- Medical subject headings
- Overweight, Obesity
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
eTRIPBehavioural
Intervention group 1 involves using the eating behaviour trigger-response inhibition program(eTRIP) smartphone application for 10 weeks, where participants will need to take pictures of their food items as part of their food logging and may also engage with app-based activities to build self-regulatory skills in sticking to their weight loss plans. Additionally, participants will also apply a continuous glucose monitoring (CGM) sensor on their arm and taught how to scan the CGM sensor so that they can monitor their glucose levels for the first 10 days.
FatSecretOther
Intervention group 2 involves using the FatSecret smartphone application for participants to monitor their calorie intake, without any continuous glucose monitoring.
| Study group | Role | What they receive |
|---|---|---|
| eTRIP smartphone application | Experimental | Intervention group 1 involves using the eating behaviour trigger-response inhibition program(eTRIP) smartphone application for 10 weeks, where participants will need to take pictures of their food items as part of their food logging and may also engage with app-based activities to build self-regulatory skills in sticking to their weight loss plans. Additionally, participants will also apply a continuous glucose monitoring (CGM) sensor on their arm and taught how to scan the CGM sensor so that they can monitor their glucose levels for the first 10 days. Receives: Behavioral: eTRIP |
| FatSecret smartphone application | Sham comparator | Intervention group 2 involves using the FatSecret smartphone application for participants to monitor their calorie intake, without any continuous glucose monitoring. Receives: Other: FatSecret |
| Control | No intervention | Control group will not receive any smartphone application or continuous glucose monitoring. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Height
Taken using a wall mounted measuring tape.
Measured: At weeks 0, 10 and 24.
Weight
Taken using InBody 120
Measured: At weeks 0, 10 and 24.
Waist Circumference
Taken using a measuring tape.
Measured: At weeks 0, 10 and 24.
BMI
Taken using InBody 120
Measured: At weeks 0, 10 and 24.
Self regulation of Eating Behaviour Questionnaire (SREBQ)
The Self-Regulation of Eating Behaviour Questionnaire (SREBQ) is a validated self-administered instrument used to assess individuals' self-regulation in relation to eating behavior. It evaluates the extent to which individuals monitor, control, and regulate their eating behaviors in everyday contexts. Higher scores indicate greater self-regulation of eating behavior.
Measured: At weeks 0, 10 and 24.
Secondary outcomes (12)
Patient Health Questionnaire-2 (PHQ-2)
The Patient Health Questionnaire - 2 item (PHQ-2) is a validated self-administered screening questionnaire used to assess the frequency of depressive symptoms over the past two weeks. Higher scores indicate greater depressive symptom severity.
Measured: At weeks 0, 10 and 24.
Euro Quality of life 5 Dimensions-5 Levels (EQ-5D-5L)
The EuroQol 5 Dimensions - 5 Levels (EQ-5D-5L) is a standardized self-administered instrument used to assess health-related quality of life. It measures five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression, each with five response levels.
Measured: At weeks 0, 10 and 24.
Generalized Anxiety Disorder 2-item (GAD-2)
The Generalized Anxiety Disorder - 2 item (GAD-2) is a validated self-administered screening questionnaire used to assess the frequency of core anxiety symptoms over the past two weeks. Higher scores indicate greater anxiety symptom severity.
Measured: At weeks 0, 10 and 24.
Percentage Body Fat
Taken using InBody 120.
Measured: At weeks 0, 10 and 24.
Body Fat Mass
Taken using InBody 120.
Measured: At weeks 0, 10 and 24.
Three Factor Eating Questionnaire (TFEQ)
The Three-Factor Eating Questionnaire (TFEQ) is a validated self-administered instrument used to assess eating-related behaviors. It measures three domains: cognitive restraint of eating, uncontrolled eating, and emotional eating. Higher scores indicate greater levels of the respective eating behavior.
Measured: At weeks 0, 10 and 24.
International Physical Activity Questionnaire Short-Form (IPAQ-SF)
The International Physical Activity Questionnaire - Short Form (IPAQ-SF) is a validated self-administered questionnaire used to assess self-reported physical activity levels. It captures the frequency and duration of walking, moderate-intensity activity, and vigorous-intensity activity performed over the past 7 days.
Measured: At weeks 0, 10 and 24.
Self-Report Behavioural Automaticity Index (SRBAI)
The Self-Report Behavioural Automaticity Index (SRBAI) is a validated self-administered questionnaire used to assess the automaticity of behavior. It evaluates the extent to which a behavior is performed automatically, with little conscious thought or deliberation. Higher scores indicate greater behavioral automaticity.
Measured: At weeks 0, 10 and 24.
Consideration of Future Consequences Scale (CFCS-6)
The Consideration of Future Consequences Scale - 6 item (CFCS-6) is a validated self-administered questionnaire used to assess the extent to which individuals consider the potential future outcomes of their current behaviors. It evaluates the degree to which individuals weigh immediate versus future consequences when making decisions. Higher scores indicate greater consideration of future consequences.
Measured: At weeks 0, 10 and 24.
Skeletal Muscle Mass
Taken using InBody 120.
Measured: At weeks 0,10 and 24.
Visceral Fat Level
Taken using InBody 120.
Measured: At weeks 0, 10 and 24.
Big Five Inventory - 44 item (BFI-44)
The Big Five Inventory - 44 item (BFI-44) is a validated self-administered questionnaire used to assess personality traits across five domains: openness, conscientiousness, extraversion, agreeableness, and neuroticism. Higher scores indicate greater expression of the respective personality traits.
Measured: At weeks 0, 10 and 24.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted9 Feb 2026
- Study start22 Jan 2025
- Primary completionJul 2026 (estimated)
- Study completionJul 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Overweight , ObesityStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- National University Health System, Singapore
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jocelyn Chew, National University Health System, Singapore
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07395466
- Sponsor's protocol ID
- NUS-IRB-2023-597
- Status last verified
- Jan 2026
- First submitted
- 24 Jun 2025
- Last updated
- 9 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 9 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Improving Weight Loss in Healthy Adults With Overweight and Obesity: An Artificial Intelligence-assisted Dietary Prediction and Prevention System With Continuous Glucose Monitoring
- ClinicalTrials.gov ID
- NCT07395466
- Acronym / sponsor ID
- NUS-IRB-2023-597
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- National University Health System, SingaporeUniversity, hospital or other
- Study start
- 22 Jan 2025 (actual)
- Primary completion
- Jul 2026 (estimated)
- Study completion
- Jul 2026 (estimated)
- First posted
- 9 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to examine the effectiveness of a novel dietary lapse prediction and prevention self-regulation app called the eating behaviour trigger-response inhibition program (eTRIP), and the addition of continuous glucose monitoring (CGM), on healthy eating and weight loss in people with overweight and obesity.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| eTRIP smartphone application | Experimental | Behavioral: eTRIPIntervention group 1 involves using the eating behaviour trigger-response inhibition program(eTRIP) smartphone application for 10 weeks, where participants will need to take pictures of their food items as part of their food logging and may also engage with app-based activities to build self-regulatory skills in sticking to their weight loss plans. Additionally, participants will also apply a continuous glucose monitoring (CGM) sensor on their arm and taught how to scan the CGM sensor so that they can monitor their glucose levels for the first 10 days. |
| FatSecret smartphone application | Sham comparator | Other: FatSecretIntervention group 2 involves using the FatSecret smartphone application for participants to monitor their calorie intake, without any continuous glucose monitoring. |
| Control | No intervention | –Control group will not receive any smartphone application or continuous glucose monitoring. |
Who may qualify
- Ages
- 21 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- are 21-65 years old
- have BMI ≥23 kg/m2
- can comprehend the English language
- uses a smartphone that can download apps
- are willing to perform continuous glucose monitoring (CGM) using the Dexcom continuous glucose monitoring system
Key exclusion criteria (6 listed)
- are using/intend to use other apps for weight loss;
- are pregnant or lactating (as it would affect weight change and caloric needs)
- are diagnosed severe mental disorders (e.g. major depressive disorder and schizophrenia)
- are on prescribed meal replacements or pharmacotherapy
- have serious medical conditions
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| eTRIPIntervention group 1 involves using the eating behaviour trigger-response inhibition program(eTRIP) smartphone application for 10 weeks, where participants will need to take pictures of their food items as part of their food logging and may also engage with app-based activities to build self-regulatory skills in sticking to their weight loss plans. Additionally, participants will also apply a continuous glucose monitoring (CGM) sensor on their arm and taught how to scan the CGM sensor so that they can monitor their glucose levels for the first 10 days. | Behavioural | eTRIP smartphone application |
| FatSecretIntervention group 2 involves using the FatSecret smartphone application for participants to monitor their calorie intake, without any continuous glucose monitoring. | Other | FatSecret smartphone application |
Primary outcome
Height
Time frame: At weeks 0, 10 and 24.
Taken using a wall mounted measuring tape.
Weight
Time frame: At weeks 0, 10 and 24.
Taken using InBody 120
Waist Circumference
Time frame: At weeks 0, 10 and 24.
Taken using a measuring tape.
BMI
Time frame: At weeks 0, 10 and 24.
Taken using InBody 120
Self regulation of Eating Behaviour Questionnaire (SREBQ)
Time frame: At weeks 0, 10 and 24.
The Self-Regulation of Eating Behaviour Questionnaire (SREBQ) is a validated self-administered instrument used to assess individuals' self-regulation in relation to eating behavior. It evaluates the extent to which individuals monitor, control, and regulate their eating behaviors in everyday contexts. Higher scores indicate greater self-regulation of eating behavior.
12 secondary outcomes
Patient Health Questionnaire-2 (PHQ-2)
Time frame: At weeks 0, 10 and 24.
Euro Quality of life 5 Dimensions-5 Levels (EQ-5D-5L)
Time frame: At weeks 0, 10 and 24.
Generalized Anxiety Disorder 2-item (GAD-2)
Time frame: At weeks 0, 10 and 24.
Percentage Body Fat
Time frame: At weeks 0, 10 and 24.
Body Fat Mass
Time frame: At weeks 0, 10 and 24.
Three Factor Eating Questionnaire (TFEQ)
Time frame: At weeks 0, 10 and 24.
International Physical Activity Questionnaire Short-Form (IPAQ-SF)
Time frame: At weeks 0, 10 and 24.
Self-Report Behavioural Automaticity Index (SRBAI)
Time frame: At weeks 0, 10 and 24.
Consideration of Future Consequences Scale (CFCS-6)
Time frame: At weeks 0, 10 and 24.
Skeletal Muscle Mass
Time frame: At weeks 0,10 and 24.
Visceral Fat Level
Time frame: At weeks 0, 10 and 24.
Big Five Inventory - 44 item (BFI-44)
Time frame: At weeks 0, 10 and 24.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 9 Feb 2026.
- Individual participant dataSharing planned: No
Related trials for Overweight , Obesity
RecruitingObservational study
Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)
Obesity
Active, not recruitingPhase 4
Effects of Sequential Therapy With Mexidol® (Intravenous) and Mexidol® FORTE 250 (Oral) on Functional Brain Activity Assessed by Functional Magnetic Resonance Imaging and Biochemical Parameters in Patients With Chronic Cerebral Ischemia: A Comparison of Patients With and Without Metabolic Disorders
Metabolic Abnormalities, Obesity & Overweight
Recruiting
Exercise Training and Vitamin D Metabolism
Obesity & Overweight, Vitamin D
Recruiting
Metabolic Health, Bones and Nuts During Weight Loss in Adults
Weight Loss, Bone Density
Active, not recruiting
Effect of Probiotics on Insulin Sensitivity in Overweight and Obese Pregnancy
Obesity & Overweight, Gestational Diabetes Mellitus (GDM)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing eTRIP and FatSecret in people with Overweight , Obesity and Overweight or Obese Adults, run by National University Health System, Singapore at 1 site in Singapore.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 9 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Height (time frame: At weeks 0, 10 and 24.). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Feb 2026.